Extracorporeal Membrane Oxygenation, Pharmacokinetics, Tigecycline
Conditions
Brief summary
Tigecycline is a commonly used antibiotic in critically ill patients. The pharmacokinetics (PK) of tigecycline in intensive care unit (ICU) patients can be affected by severe pathophysiological changes so that standard dosing might not be adequate. At present, a number of studies have reported that ECMO will affect the PK of anti-infective drugs and lead to treatment failure. The purpose of this study was to describe the population PK of tigecycline in patients treated with ECMO and to evaluate the relationship between individual PK parameters and patient covariates.
Interventions
None listed
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* critically ill hospitalized males or nonpregnant females aged ≥18 years with severe infections which the treating clinician was treating with tigecycline.
Exclusion criteria
* People who had taken tigecycline in the past week * People who were pregnant * People who had coagulation dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum drug concentration of tigecycline | predose, 2 min, 5 min, 15 min, 30 min, 1 hour, 3 hours, 6 hours, 12 hours, and 24 hours post-dose | Serum drug concentration at different time points in each adult ICU patient treated with ECMO |
Countries
China
Contacts
Primary ContactYuan Zhang, doctor
Backup ContactZhenhua Zeng, doctor
Outcome results
None listed